Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Rated “Hold” by Sell-Side Brokerages

Posted by Andrew Walz on Oct 20th, 2026

Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) has been given an average recommendation of “Hold” by the eleven ratings firms that are presently covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company.

ZLDPF has been the subject of a number of recent analyst reports. Barclays lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Zacks Research upgraded shares of Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a report on Monday, October 12th. Finally, Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th.

Check Out Our Latest Stock Analysis on Zealand Pharma A/S

Zealand Pharma A/S Trading Down 1.8%

Shares of ZLDPF opened at $33.39 on Tuesday. The stock has a market capitalization of $2.39 billion, a PE ratio of 5.54 and a beta of 0.95. The company’s fifty day moving average is $44.12 and its 200 day moving average is $45.83. The company has a debt-to-equity ratio of 0.02, a quick ratio of 13.98 and a current ratio of 13.98. Zealand Pharma A/S has a fifty-two week low of $33.39 and a fifty-two week high of $83.12.

About Zealand Pharma A/S

(Get Free Report)

Zealand Pharma A/S is a biotechnology company headquartered in Denmark that discovers, develops and commercializes peptide-based medicines. Its research focuses primarily on metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs through its expertise in peptide chemistry and drug delivery.

Zealand’s marketed product portfolio includes Zegalogue (dasiglucagon), an emergency treatment for severe hypoglycemia in people with diabetes.